The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The therapeutic effect of transarterial chemoembolization (TACE) against hepatocellular carcinoma (HCC) is usually assessed using multidetector computed tomography (MDCT). However, dense lipiodol depositions can mask the enhancement of viable HCC tissue in MDCT. Contrast-enhanced ultrasonography (CEUS) could be effective in detecting small areas of viability and patency in vessels. We investigated whether arterial enhancement in CEUS after treatment with TACE can be used to detect HCC viability earlier than when using MDCT. Methods: Twelve patients received CEUS, MDCT, and gadoxetic-acid-enhanced dynamic magnetic resonance imaging (MRI) at baseline and 4 and 12 weeks after TACE. The definition of viable HCC was defined as MRI positivity after 4 or 12 weeks. Results: Eight of the 12 patients showed MRI positivity at 4 or 12 weeks. All patients with positive CEUS findings at 4 weeks (n=8) showed MRI positivity and residual viable HCC at 4 or 12 weeks. Five of the eight patients with positive CEUS findings at 4 weeks had negative results on the 4-week MDCT scan. Four (50%) of these eight patients did not have MRI positivity at 4 weeks and were ultimately confirmed as having residual HCC tissue at the 12-week MRI. Kappa statistics revealed near-perfect agreement between CEUS and MRI (κ=1.00) and substantial agreement between MDCT and MRI (κ=0.67). Conclusions: In the assessment of the response to TACE, CEUS at 4 weeks showed excellent results for detecting residual viable HCC, which suggests that CEUS can be used as an early additive diagnosis tool when deciding early additional treatment with TACE. (Clin Mol Hepatol 2015;21:165-174)
Abstract
Background/Aims: The therapeutic effect of transarterial chemoembolization (TACE) against hepatocellular carcinoma (HCC) is usually assessed using multidetector computed tomography (MDCT). However, dense lipiodol depositions can mask the enhancement of viable HCC tissue in MDCT. Contrast-enhanced ultrasonography (CEUS) could be effective in detecting small areas of viability and patency in vessels. We investigated whether arterial enhancement in CEUS after treatment with TACE can be used to detect HCC viability earlier than when using MDCT. Methods: Twelve patients received CEUS, MDCT, and gadoxetic-acid-enhanced dynamic magnetic resonance imaging (MRI) at baseline and 4 and 12 weeks after TACE. The definition of viable HCC was defined as MRI positivity after 4 or 12 weeks. Results: Eight of the 12 patients showed MRI positivity at 4 or 12 weeks. All patients with positive CEUS findings at 4 weeks (n=8) showed MRI positivity and residual viable HCC at 4 or 12 weeks. Five of the eight patients with positive CEUS findings at 4 weeks had negative results on the 4-week MDCT scan. Four (50%) of these eight patients did not have MRI positivity at 4 weeks and were ultimately confirmed as having residual HCC tissue at the 12-week MRI. Kappa statistics revealed near-perfect agreement between CEUS and MRI (κ=1.00) and substantial agreement between MDCT and MRI (κ=0.67). Conclusions: In the assessment of the response to TACE, CEUS at 4 weeks showed excellent results for detecting residual viable HCC, which suggests that CEUS can be used as an early additive diagnosis tool when deciding early additional treatment with TACE. (Clin Mol Hepatol 2015;21:165-174)
참고문헌 (36)
- Bruix J, "European Association for the Study of the Liver", J Hepatol, 2001, pp.421~430
- Maluccio M, "Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma", CA Cancer J Clin, 62, pp.394~399 (2012)
- Lau WY, "Hepatocellular carcinoma : current management and recent advances", Hepatobiliary Pancreat Dis Int, 7, pp.237~257 (2008)
- Poon RT, "Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function : implications for a strategy of salvage transplantation", Ann Surg, 235, pp.373~382 (2002)
- Torzilli G, "No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients : is there a way? A prospective analysis of our approach", Arch Surg, 134, pp.984~992 (1999)
- Cioni D, "Therapeutic effect of transcatheter arterial chemoembolization on hepatocellular carcinoma : evaluation with contrast-enhanced harmonic power Doppler ultrasound", Eur Radiol, 10, pp.1570~1575 (2000)
- Ding H, "Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US : comparison with dynamic CT", Radiology, 221, pp.721~730 (2001)
- Choi H, "Radio-frequency ablation of liver tumors: assessment of therapeutic response and complications", Radiographics, 21, pp.S41~S54 (2001)
- Kim SH, "Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization : usefulness of attenuation value measurement at quadruplephase helical computed tomography", J Comput Assist Tomogr, 31, pp.198~203 (2007)
- Park MH, "Spectrum of CT findings after radiofrequency ablation of hepatic tumors", Radiographics, 28, pp.379~390 (2008)
- Kim MY, "Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis", Hepatology, 56, pp.1053~1062 (2012)
- Kim MY, "Invasive and non-invasive diagnosis of cirrhosis and portal hypertension", World J Gastroenterol, 20, pp.4300~4315 (2014)
- Kim CK, "Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma : utility of contrast-enhanced agent detection imaging", Eur J Radiol, 56, pp.66~73 (2005)
- Malagari K, "Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads : results of an open-label study of 62 patients", Cardiovasc Intervent Radiol, 31, pp.269~280 (2008)
- Moschouris H, "Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads : a pilot study focused on sustained tumor necrosis", Cardiovasc Intervent Radiol, 33, pp.1022~1027 (2010)
- Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
- "Practice guidelines for management of hepatocellular carcinoma 2014"[URL]
- European Association for the Study of the Liver EOfRaToC, "EASLEORTC clinical practice guidelines : management of hepatocellular carcinoma", Eur J Cancer, 48, pp.599~641 (2012)
- Jang JY, "Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions", Clin Mol Hepatol, 19, pp.1~16 (2013)
- The Usefulness of Contrast-Enhanced Ultrasonography in the Diagnosis of Hepatocellular Carcinoma, "Kim MY", The Korean Liver Cancer Study Group, 7~13 (2014)
- Landis JR, "The measurement of observer agreement for categorical data", Biometrics, 33, pp.159~174 (1977)
- Bismuth H, "Primary treatment of hepatocellular carcinoma by arterial chemoembolization", Am J Surg, 163, pp.387~394 (1992)
- Nakamura H, "Transcatheter embolization of hepatocellular carcinoma : assessment of efficacy in cases of resection following embolization", Radiology, 147, pp.401~405 (1983)
- Hsu HC, "Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization", Cancer, 57, pp.1184~1191 (1986)
- Kim AY, "Hepatocellular carcinoma : power Doppler US with a contrast agent--preliminary results", Radiology, 209, pp.135~140 (1998)
- Tanaka K, "Color Doppler sonography of hepatocellular carcinoma before and after treatment by transcatheter arterial embolization", AJR Am J Roentgenol, 158, pp.541~546 (1992)
- Bartolozzi C, "Hepatocellular carcinoma : CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection", Radiology, 191, pp.123~128 (1994)
- Kubota K, "Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI", Abdom Imaging, 26, pp.184~190 (2001)
- Ricci P, "Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma?", Ultraschall Med, 30, pp.252~258 (2009)
- Choi BI, "Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma : CT and pathologic findings", Radiology, 182, pp.709~713 (1992)
- Catalano O, "Hepatocellular carcinoma treated with chemoembolization : assessment with contrast-enhanced doppler ultrasonography", Cardiovasc Intervent Radiol, 22, pp.486~492 (1999)
- De Santis M, "MRI of hepatocellular carcinoma before and after transcatheter chemoembolization", J Comput Assist Tomogr, 17, pp.901~908 (1993)
- Shinagawa Y, "Pseudolesion of the liver on gadoxetate disodiumenhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma : clinicoradiologic correlation", AJR Am J Roentgenol, 199, pp.1010~1017 (2012)
- Kim HJ, "Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization : comparison of contrast-enhanced sonography and 3-phase computed tomography", J Ultrasound Med, 25, pp.477~486 (2006)
- Ding H, "Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma", AJR Am J Roentgenol, 176, pp.661~666 (2001)
- Dill-Macky MJ, "Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrastenhanced sonography", AJR Am J Roentgenol, 186, pp.S287~S295 (2006)